2022-06-132022-06-132015-11Sarandöl, A. vd. (2015). "First-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment". Psychiatry and Clinical Neurosciences, 69(11), 699-707.1323-1316https://doi.org/10.1111/pcn.12333https://onlinelibrary.wiley.com/doi/10.1111/pcn.12333http://hdl.handle.net/11452/27089AimsIn the present study, our aim was to investigate the oxidative-antioxidative systems in unmedicated first-episode psychosis (FEP) patients at the beginning and after short-term treatment. MethodsThis study consisted of 29 patients who experienced an FEP and 25 control subjects. In order to investigate the oxidative status, we determined plasma malondialdehyde (MDA) levels, oxidizability of red blood cells, oxidation and oxidizability of apolipoprotein B-containing lipoproteins (apo B-basal MDA and apo B-MDA). In order to evaluate the antioxidative defense, we measured serum total antioxidative capacity, uric acid, albumin, total bilirubin and vitamin E levels and serum paraoxonase/arylesterase, whole blood glutathione peroxidase (GPx) and red blood cell superoxide dismutase activities before and after 6 weeks of treatment in patients with FEP. ResultsPlasma MDA and apo B-basal MDA levels and red blood cell superoxide dismutase activity were significantly higher and serum arylesterase and whole blood-GPx activities were lower in the FEP group than those of the healthy control group. There were not any significant changes in the oxidative and antioxidative system parameters (except increased vitamin E levels) after treatment. ConclusionsThe results of this study suggest that FEP is accompanied by oxidative stress. However, further studies are needed to clarify the role of oxidative stress in the physiopathologic mechanisms of FEP, so that oxidative and antioxidative system parameters can be used in the management of these patients. In accordance with psychiatric evaluation, for a better management, patients with FEP may require a multidisciplinary approach, including oxidative and antioxidative system parameters.eninfo:eu-repo/semantics/closedAccessAffective disordersAntioxidantFirst-episode psychosisOxidative stressSchizophreniaLow-density-lipoproteinDrug-naive patientsAntioxidant defenseLipid peroxideSschizophreniaPlasmaOnsetSusceptibilityDiseaseNeurosciences & neurologyPsychiatryAdultAntipsychotic agentsApolipoprotein B-100AryldialkylphosphataseBilirubinCarboxylic ester hydrolasesCase-control studiesErythrocytesFemaleGlutathione peroxidaseHumansMaleMalondialdehydeOxidation-reductionOxidative stressPsychotic disordersSerum albuminSuperoxide dismutaseUric acidVitamin EYoung adultArticle0003638919000052-s2.0-84945458763699707691126172069Clinical neurologyNeurosciencesPsychiatryOxidative Stress; Acetylcysteine; Bipolar DisorderAlbuminAlpha tocopherolApolipoprotein BAryldialkylphosphataseArylesteraseBilirubinGlutathione peroxidaseMalonaldehydeNeuroleptic agentSuperoxide dismutaseUric acidALB protein, humanAlpha tocopherolAPOB protein, humanApolipoprotein B100AryldialkylphosphataseArylesteraseBilirubinCarboxylesteraseGlutathione peroxidaseMalonaldehydeNeuroleptic agentSerum albuminSuperoxide dismutaseUric acidAdultArticleClinical articleClinical evaluationControlled studyEnzyme activityEnzyme blood levelErythrocyteFemaleHumanMaleOxidationOxidative stressPathophysiologyPatient careProtein blood levelPsychosisShort course therapyVitamin blood levelBloodCase control studyDrug effectsMetabolismOxidation reduction reactionOxidative stressPsychotic disordersYoung adult